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Abstract 
 
Purpose: To increase psychiatric providers’ adherence to the recommendations set forth 
in the American Psychiatric Association Consensus Guideline for metabolic management 
of patients prescribed second generation antipsychotic medications (SGAs).  
Background: Research suggests that SGAs increase the indicators of metabolic 
syndrome and a need exists in collecting patients’ biometrics that influences metabolic 
management. 
Methods: Guided by the Iowa Model of Research in Practice, baseline data was collected 
on blood pressure and body mass index documentation.  Metabolic management 
education was provided to providers in a community behavioral health clinic and four 
weeks of post data was collected. 
Results: A 70% increase in the compliance of blood pressure documentation and a 
58.23% increase in body mass index documentation were noted from the baseline data to 
the post education data.  
Conclusions: This evidenced-based practice project is the first step in the process of 
shifting psychiatric provider behavior in adhering to the guidelines for metabolic 
management of the patients prescribed SGAs. 
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Background 
Antipsychotic medications are an integral component of treatment for many 
psychiatric disorders and psychiatric symptoms.  Given that treatment for many common 
psychiatric disorders often requires lifelong psychotropic management and that as a 
profession, psychiatry often prescribes antipsychotics for off label uses; the demand for 
antipsychotic medication has significantly increased over the past generation.
1, 3, 4, 6 
Typically prescribed for psychosis, first generation antipsychotics (FGAs) were 
developed in the 1950’s and often referred to as “neuroleptics” because of their capacity 
to affect psychomotor slowing, emotional quieting and affective indifference. 
Regrettably, FGAs also have a higher risk of neurological side effects including tardive 
dyskinesia and extrapyramidal dystonia.
1 
Second generation antipsychotics (SGAs) came onto the market in the 1980’s. 
Also called “atypical”, these newer SGAs demonstrated a lower risk of neurological side 
effects, but in time, were linked with a proven risk of developing metabolic side effects 
including weight gain with an increase in waist circumference, hyperglycemia, 
dyslipidemia subsequently leading to cardiovascular disease and/or diabetes.
1,3,4,6 
Recognizing the severe chronicity of the consequences of the metabolic side 
effects of the atypical antipsychotic medications, in 2003 the American Diabetes 
Association, the American Psychiatric Association, the American Association of Clinical 
Endocrinologists, and the North American Association for the Study of Obesity 
(ADA/APA/ACE/NAASO) convened at a conference creating a consensus position 
statement and monitoring screening protocol for patients prescribed SGAs.
1 
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.  
Purpose 
Staffed with psychiatric physician residents, an attending physician, and a newly 
hired psychiatric nurse practitioner (PMHNP), the psychiatric behavioral health clinic is 
currently operational two afternoons a week.  Averaging 33 psychiatric visits each 
afternoon, the current patient volume does not provide justification for the hiring of a 
medical assistant.  Any biometrics or baseline data such as blood pressure, height, 
weight, or waist circumference needs to be obtained and documented by the clinic 
psychiatric providers themselves at the time of the psychiatric visit.  
The aim of this evidence based practice (EBP) project was to provide improved 
patient care by increasing the psychiatric providers’ adherence to the recommendations 
created by the Consensus Development Conference on Antipsychotic Drugs, Obesity, and 
Diabetes for metabolic screening and treatment of patients prescribed SGAs.  Psychiatric 
providers prescribing SGAs should ensure, according to the consensus guidelines 
established by the conference, that a baseline blood pressure, height and weight for a 
body mass calculation, and waist circumference measurement are documented in the 
electronic health record (EHR).
1,3,4,11,12
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Synthesis of the Evidence 
 A literature search revealed Meta-analysis evidence, as well as individual 
experimental case and cohort studies to validate the monitoring protocol noted in Table 1; 
established in 2003 by the Consensus Development Conference on Antipsychotic Drugs 
and Obesity.
3,4,8,11   
Table 1 Metabolic Monitoring Protocol 
 Baseline 4 weeks 8 weeks 12 weeks Quarterly Annually Q 5 
Years 
Family 
History 
X     X  
Weight 
(BMI) 
X X X X X   
Waist 
Circumference 
X     X  
Blood 
Pressure 
X   X  X  
Fasting 
Plasma 
Glucose 
X   X  X  
Fasting lipid 
profile 
X   X   X 
 
The Conference observed that although trends have been identified linking SGAs 
and obesity or diabetes, the majority of studies and subsequent data focused on those 
patients with a diagnosis of schizophrenia. Within the population of patients who carry a 
diagnosis of schizophrenia, weight gain and accompanying changes in body composition 
during the psycho-pharmaceutical treatment with SGAs weight gain is significantly 
evident. The weight gain and physical changes are frequently combined with 
dyslipidemia and the subsequent development of diabetes.
1, 2, 3, 9, 10 
During the course of treatment with SGAs, clinicians who prescribe the SGAs 
should be monitoring weight through the entire term of treatment. Additionally, the 
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baseline and periodic monitoring of blood pressure, waist circumference, and laboratory 
values should be routinely assessed.
1, 8 
 The reasons why SGAs cause metabolic changes is not fully understood.  The six 
SGAs, noted in Table 2, differ in chemical makeup and efficacy and some contribute to  
metabolic changes more than others. The SGA medications are not created equal nor are 
they prescribed interchangeably for psychiatric conditions and symptomology. The risk 
versus benefit to the patient who is prescribed a particular SGA and the “return on 
investment” in alleviating symptoms needs to be taken into consideration even while 
monitoring for metabolic shifts. For some, the efficacy of management of the psychiatric 
symptoms, regardless of the metabolic risks or changes, outweighs any consideration to 
switch to an alternate medication.
4, 5, 6, 8 
Table 2  Second Generation Antipsychotics  
Generic Name Trade Name Year Approved 
Clozapine Clozaril 1989 
Risperidone Risperdal 1993 
Olanzapine Zyprexa 1996 
Quetiapine Seroquel 1997 
Ziprasidone Geodon 2001 
Aripiprazole Abilify 2001 
 
Practice Change 
 The psychiatrist residents as providers at the psychiatric behavioral health clinic 
were observed to rarely be obtaining a baseline blood pressure on adult patients. The 
clinic had made available stethoscopes and two manual blood pressure cuffs occasionally 
used by the psychiatric providers for obtaining a blood pressure reading. The newly 
adopted EHR did have provision in the psychiatric visit documentation template for the 
baseline biometrics, yet, because the clinic did not have a scale during the retrospective 
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data period, height, weight, or body mass index were not being documented at the time of 
the psychiatric visit. 
Despite the acceptance and acknowledgement of the importance of the guideline, 
psychiatric clinics as a whole do not appear to be routinely following the 
ADA/APA/ACE/NAASO guideline.
6,11
  Psychiatrists are often reluctant to collect and 
document blood pressure, height and weight, and are particularly averse to measuring 
waist circumference. Provider reluctance appears to be a significant impediment to the 
overall broad implementation of this clinical guideline.
4,6,11 
Implementation 
 The practice change occurred on February 21 and 27
th
, 2017. Education on the 
ADA/APA/ACE/NAASO guideline to the psychiatric providers occurred on the same 
day. The post-implementation data was collected from the EHR from February 21, 2017 
through March 21, 2017.  For comparison, twenty four months of retrospective data from 
the EHR from July 2014 through July 2016 was collected evaluating patient charts of 
those prescribed SGAs noting whether blood pressure, BMI, or waist circumference were 
documented at the psychiatric visit. A letter of support from the clinical director was 
obtained and the request to initiate a special project was sent through the appropriate 
channels at the clinic site. The project was submitted through the USD institutional 
review board (IRB) and approval was obtained under exempt status. 
The affected staff included eight psychiatric physician resident providers, two 
attending psychiatrists, and one PMHNP. The support of the clinic director and of the 
attending psychiatrists was vital to the success of the project. The Iowa Model of 
Research in Practice was used as the implementation guide. 
7 
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Outcomes 
 Utilizing data from the EHR, the project results were intended to be evaluated on 
three objectives: a 20% increase in the documentation rate of blood pressure, a 20% 
increase over baseline in the documentation rate of body mass index, and a 20 % increase 
over baseline in the documentation of waist circumference. 
 The control chart in Table 3 below compares pre-intervention data with the results 
of the post intervention data in the blood pressure monitoring rate. The blue dots reveal 
that 5.31% of the time during the retrospective data collection period a blood pressure 
was taken and documented at the time of the psychiatric visit. In other words, a blood 
pressure was occasionally taken and documented during this time. The red dots falling 
below the mean flag an undesirable trend noting essentially 0% of the time was blood 
pressure was taken and documented at the time of the psychiatric visit. Following the 
educational intervention to the providers, an upward trajectory is noted during the month 
of post intervention data collection. The 70% documentation rate of blood pressure is 
well above the target outcome of a 20% increase over baseline. 
Table 3 
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The control chart in Table 4 below compares pre-intervention data with the results 
of the post intervention data for BP and BMI. During the retrospective data collection 
time period it was business as usual as evidenced by the blue dots. Falling below the 
mean, an undesirable trend is noted by the red dots during the retrospective data 
collection period depicting a 0% baseline documentation rate of blood pressure and/or 
BMI. Following the educational intervention to the providers, a 58.23% increase over 
baseline is noted well above the target outcome of a 20%.increase. 
Table 4  
 
For the purposes of this pilot study, difficulty in ordering the disposable tape 
measures, provider reluctance, and provider time constraints influenced cost and value in 
continuing to pursue documentation of waist circumference in the electronic health 
record at this time. The stakeholders agreed that this data point was not feasible for the 
pilot study. Therefore, for this pilot study, the standard of care in regards to the 
ADA/APA/ACE/NAASO guideline was partially met. 
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Implications for practice 
 The project heralded several unintended, yet significantly positive outcomes. 
Once it was established that blood pressure and BMI monitoring were to become a 
routine part of the psychiatric visit, a process protocol was developed in collaboration 
with the primary care and family medicine medical directors to identify and manage 
abnormal BP results. As the organization is moving towards Integrated Behavioral 
Healthcare delivery model with an emphasis on quality improvement, this level of 
collaboration between psychiatry and primary care was especially beneficial. Discussions 
were initiated on how the psychiatric clinic space could be more effectively used and a 
physical area was set aside for monitoring biometrics. The clinic director continues to the 
feasibility of utilizing a medical assistant from an alternate department to assist in the 
biometric collection on psychiatric clinic days.  A representative from the Information 
Technology department noted that the consistent documentation of blood pressures, 
height and weight at the time of the psychiatric visit enhanced the organizations’ 
participation in the Centers for Medicare and Medicaid Services Meaningful Use 
program.
12 
 Appreciating the concomitant implications for the providers in other areas of the 
clinic, this quality improvement project is the first step in the process of shifting 
psychiatric provider behavior to include adherence to the recommendations set forth in 
the guidelines for metabolic management of the patient prescribed SGA’s. 
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Conclusions 
 This evidence based practice project met its intended goal of increasing the 
psychiatric providers screening for metabolic changes by collecting baseline biometrics 
as recommended in the ADA/APA/ACE/NAASO consensus guideline. The adherence to 
the guideline is a sustainable addition to the routine care offered by the psychiatric clinic 
and a complement to the Integrated Behavioral Healthcare delivery model the 
organization has adopted. The successful implementation of the project may have long 
lasting impact on attention to metabolic changes within the behavioral health clinic 
patient population as well as integrate general healthcare screening into psychiatry 
practice for the psychiatric providers. 
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